Selank Dosage & Anxiolytic Evidence: Real Trials vs. Semax
Selank is a synthetic analog of tuftsin, a naturally occurring immune peptide, developed alongside Semax in Russia and registered there as a prescription anxiolytic. Russian trials comparing it against the benzodiazepines medazepam and phenazepam, in a combined 122 patients, report anxiolytic effect similar to those drugs without the sedation they cause, a finding tied to a real, published mechanism involving enkephalin metabolism. As with Semax, none of that evidence covers the injectable form sold to buyers outside Russia.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) · also sold or referred to as TP-7, Selank acetate
Photo: Angelina Sarycheva / UnsplashRelated peptides, different jobs.
They come from the same Russian research program and get confused constantly, but they aren’t interchangeable: different parent molecule, different trial population, and now a different regulatory path. The full Semax vs. Selank comparison breaks down the dosage, evidence, and side-effect data for both, side by side.
What the comparator trials used, and what vendors sell instead.
| What's cited | Range |
|---|---|
| GAD/neurasthenia trial (Zozulia et al. 2008, n=62, vs. medazepam) | intranasal, per Russian clinical protocol; exact mcg/day not specified in the available abstract |
| Anxiety-disorder trial (Medvedev et al. 2014, n=60, vs. phenazepam) | intranasal, over a defined treatment course; exact mcg/day not specified in the available abstract |
| Commonly cited Russian clinical-protocol dose (secondary sources, not independently verified) | 2 drops (~150 mcg) of a 0.15% intranasal solution, three times daily, for up to 14 days |
| Commonly cited nootropic/anxiolytic dose (vendor/community, intranasal) | 300-900 mcg/day, split into 2-3 doses |
| Commonly cited injectable dose (vendor-reported, zero human trials use this route) | 300-600 mcg/day, subcutaneous |
Both published comparator trials, against medazepam and against phenazepam, used Russia's standard intranasal Selank protocol, but neither abstract available to us specifies the exact daily microgram dose, only the patient count, comparator, and course length. The "2 drops, three times daily" figure below is the commonly cited Russian clinical-protocol dose from secondary sources, not something we could trace back to a primary trial ourselves, so it's presented as commonly cited, not verified. The higher vendor-cited ranges, and every injectable protocol, have no trial behind them at all.
Notable mostly for what it doesn’t cause.
| Signal | Frequency | Context |
|---|---|---|
| Nasal irritation at the instillation site | commonly reported | Consistent with intranasal delivery generally, not specific to Selank's mechanism. |
| Shifts in immune markers (IL-6, Th1/Th2 balance) | occasionally reported | A published trial in anxiety-asthenic patients measured real changes in these markers, framed by its authors as beneficial immunomodulation rather than an adverse effect, but it's a genuine physiological effect worth disclosing. |
| Sedation, muscle relaxation, or psychomotor impairment | rarely reported | The specific point of the published comparator trials is that Selank produced anxiolytic effects without the sedation and muscle relaxation typical of the benzodiazepines it was compared against. |
| Effects of injectable administration | unknown / not studied | No completed human trial has tested Selank delivered by injection. Every study cited on this page used intranasal administration. |
| Interaction with autoimmune conditions or immunosuppressant therapy | unknown / not studied | Given the measured immune-marker shifts, no published trial has specifically studied Selank in people with autoimmune disease or on immunosuppressants. |
Not FDA-approved. Registered as a prescription anxiolytic in Russia. Withdrawn from FDA Category 2, with no active US re-nomination.
Selank has never been approved by the FDA for any use. Like Semax, it has a longstanding regulatory history outside the US: Russian and secondary sources describe it as a registered prescription drug for generalized anxiety disorder and neurasthenia, a specific registration number we could not independently verify against a primary registry, so we're not repeating it as a hard fact here. In the US, the FDA lists it under its salt form, "Selank acetate (TP-7)," among bulk substances nominated for 503A Category 2 and then withdrawn, stating that compounded selank acetate "may pose risk for immunogenicity for certain routes of administration" and that the agency "lacks important information regarding any safety issues raised by selank acetate administered to humans." Unlike Semax, Selank was not on the agenda for the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting (which covers BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and epitalon), so there's no scheduled US regulatory review of Selank as of this writing.
Every claim above, traced back.
Two active-comparator Russian trials, a mechanism study, an immunomodulatory trial, a shared human brain-imaging study, and current FDA compounding records.
Selank questions, answered.
Real Russian trials, comparing it head-to-head against medazepam (62 patients) and phenazepam (60 patients), report comparable anxiolytic effect without the sedation or muscle relaxation those benzodiazepines cause. That's a genuine finding, but both were open-label, active-comparator trials run in specific Russian patient populations, not the placebo-controlled, internationally-registered trials that would back an FDA approval.
No. It's registered in Russia as a prescription anxiolytic, not in the US. The FDA lists it (as "Selank acetate (TP-7)") among bulk substances nominated for its Category 2 compounding-restricted list and then withdrawn, citing a lack of safety information for its proposed routes of administration.
Selank is a synthetic analog of tuftsin, a naturally occurring immune peptide. A published mechanism study found it dose-dependently inhibits the enzymes that break down enkephalins (the body's own opioid-like signaling peptides), which is the proposed reason it produces anxiolytic effects without classic sedative side effects.
They're related but built for different jobs. Semax is derived from ACTH and studied mainly for stroke recovery and cognitive/neuroprotective effects; Selank is derived from tuftsin and studied for anxiety and neurasthenia. One published human study scanned 52 healthy volunteers on both peptides in the same design and found distinct effects on brain connectivity for each, so they aren't interchangeable versions of the same thing.
Keep researching.
This is a preview of the Selank report.
Create your account to check any peptide against the full research base.